Shanghai Henlius Wins China Approval for Phase 1 Trial of HLX105 Cancer TreatmentPUBT·Nov 16, 2026 at 08:32 AM02696-0.96%
Henlius Announces HANSIZHUANG and FUTUONING Additions to 2026 NRDLTip Ranks·Nov 15, 2026 at 10:39 AM02696-0.96%
Shanghai Henlius Biotech, Inc. Class H (2696) Receives a Buy from Guotai HaitongTip Ranks·Nov 11, 2026 at 05:35 AM02696-0.96%
Could Serplulimab Trial Results Alter The Investment Case For Henlius Stock?Simplywall·Nov 10, 2026 at 04:41 PM02696-0.96%
Shanghai Henlius Wins Australian Approval for Phase 1 Trial of HLX109PUBT·Nov 4, 2026 at 08:32 AM02696-0.96%
Shanghai Henlius Proposes Raising 2026 HLX01 Collaboration Cap to RMB 714 MillionPUBT·Nov 2, 2026 at 08:33 AM02696-0.96%
Shanghai Henlius Board Backs Raising 2026 HLX01 Annual Transaction Cap to RMB 714 MillionPUBT·Oct 27, 2026 at 12:23 PM02696-0.96%
Henlius reports positive results from ASTRIDE U.S. bridging study for serplulimab in combination with chemotherapy for first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC)prnewswire·Oct 27, 2026 at 08:25 AM02696-0.96%